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Abstract
Introduction Vitamin D receptor (VDR) genotypes may
influence breast cancer risk by altering potential
anticarcinogenic effects of vitamin D, but epidemiological
studies have been inconsistent. Effect modification by serum
25-hydroxyvitamin D (25 [OH]D), the biomarker for vitamin D
status in humans, has rarely been examined.
Methods We assessed the effects of two frequently analyzed
polymorphisms (FokI and TaqI) and two potentially functional
variants (VDR-5132 and Cdx2) in the VDR gene, which thus far
have not been analyzed with respect to breast cancer risk, on
postmenopausal breast cancer risk in a population-based, case-
control study including 1,408 patients (cases) and 2,612
control individuals (controls) matched for year of birth. Odds
ratios (ORs) for breast cancer adjusted for potential
confounders were calculated for genotypes and estimated
haplotypes.
Results No differences in serum 25(OD)D concentrations by
VDR  genotype were observed. None of the analyzed
polymorphisms was associated with overall risk for
postmenopausal breast cancer. However, the TaqI
polymorphism was associated with a significantly increased risk
for oestrogen receptor positive tumours (OR = 1.18, 95%
confidence interval [CI] = 1.00 to 1.38, comparing t allele
carriers with noncarriers) but not for oestrogen receptor
negative tumours (OR = 0.88, 95% CI = 0.69 to 1.13; P for
interaction = 0.04). Haplotype analysis revealed the haplotype
FtCA (FokI F, TaqI t, VDR-5132 C, Cdx2 A), which contains the
TaqI t allele, to be associated with a significantly greater breast
cancer risk as compared with the most frequent haplotype
FTCG (OR = 1.43, 95% CI = 1.00 to 2.05). No significant
interaction between VDR  genotypes or haplotypes and
25(OH)D was observed.
Conclusion Our results support potential effects of VDR
polymorphisms on postmenopausal breast cancer risk and
possible differential effects of receptor status of the tumour.
However, further studies focusing on the influence of
polymorphisms and haplotypes on VDR functionality, activity
and concentration are needed.
Introduction
In various observational studies vitamin D intake and serum
concentrations of vitamin D metabolites have been associated
with decreased risk for developing breast cancer [1-3]. Apart
from the role that vitamin D plays in maintaining calcium home-
ostasis, its antiproliferative effects – by influencing cell differ-
entiation, cell growth and apoptosis – are well established [4-
6].
Vitamin D from both diet and endogenous production is con-
verted via two consecutive hydroxylation steps to 25-hydroxy-
vitamin D (25 [OH]D) and to 1,25-dihydroxyvitamin D (1,25
[OH]2D). The biologically most active form of vitamin D is
1,25(OH)2D, which mainly exerts its antiproliferative effects by
binding to the vitamin D receptor (VDR) and acting in complex
as a transcriptional factor for a variety of genes, including
those involved in cell differentiation and cell growth [7]. The
VDR is present in a variety of cell types, including malignant
1,25(OH)2D = 1,25-dihydroxyvitamin D; 25(OH)D = 25-hydroxyvitamin D; CI = confidence interval; ER = oestrogen receptor; HWE = Hardy-Wein-
berg equilibrium; NHS = Nurses Health Study; OR = odds ratio; PCR = polymerase chain reaction; PR = progesterone receptor; R-N-K = Rhein-
Neckar-Karlsruhe; SNP = single nucleotide polymorphism; VDR = vitamin D receptor.Breast Cancer Research    Vol 10 No 2    Abbas et al.
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and normal breast cells [8,9]. Various studies have assessed
associations between various polymorphisms in the VDR gene
and breast cancer risk, with inconsistent results. These poly-
morphisms include three frequently analyzed, highly linked sin-
gle nucleotide polymorphisms (SNPs) BsmI, ApaI and TaqI at
the 3' end of the VDR gene. The t allele of the TaqI SNP in
exon 9 (rs731236, T/C, C = t), which leads to a silent codon
change, has been found in different studies to be associated
with a nonsignificantly increased breast cancer risk [10] and
with a decreased risk for breast cancer [11], or there was no
association at all [12-17].
Another promising functional polymorphism in the start codon
at the 5' promotor region of the VDR  is the FokI SNP
(rs2228570/rs10735810, T/C, T = f). The f allele leads to a
protein that is three amino acids longer and less effective
[18,19] and was associated with a statistically significant
increased breast cancer risk in a case-control study nested
within the Nurses Health Study (NHS) [20]. However, other
studies did not find any association [11,14,21-23]. Further-
more, two potentially functional polymorphisms [24-26]
located in two transcription factor binding sites within the VDR
promoter region have been reported: VDR-5132 (rs1989969,
T/C), which has been related to a potential elimination of a
GATA-1 transcription factor binding site [25]; and Cdx2
(rs11568820, G/A), which leads to decreased transcriptional
activity of the VDR promoter [26]. The Cdx2 polymorphism
has been associated with risk for bone fracture [27,28] and
with risk for prostate cancer in 25(OH)D deficient men [29];
the VDR-5132 polymorphism has been related to risk for pros-
tate cancer [25]. To our knowledge, neither polymorphism has
yet been examined with respect to breast cancer risk.
The majority of studies assessing polymorphisms in the VDR
gene and breast cancer risk have been very small and have
often failed to account for known breast cancer risk factors
and potential confounders in their analyses. Only one study
has thus far assessed the association of breast cancer risk and
VDR gene polymorphisms in relation to serum 25(OH)D [20],
and it found no significant interactions. We recently reported
an inverse association between serum 25(OH)D concentra-
tion and postmenopausal breast cancer risk in a large German
case-control study [30]. We therefore assessed the associa-
tion of FokI, TaqI, VDR-5132 and Cdx2 SNPs and their asso-
ciated haplotypes with postmenopausal breast cancer risk
and possible effect modification by serum 25(OH)D in this
study population.
Materials and methods
Study population and data collection
We conducted a large population-based, case-control study
(MARIE [Mamma Carcinoma Risk factor Investigation] study)
that was conducted in two regions in Germany: the city of
Hamburg and the Rhein-Neckar-Karlsruhe (R-N-K) region. The
study was approved by the ethics committees of both the Uni-
versity of Heidelberg and the University of Hamburg, and it
was conducted in accordance with the Declaration of Helsinki.
All study participants gave informed consent. Patients (cases)
were eligible if they had a histologically confirmed primary inva-
sive or in situ breast cancer diagnosed between 1 January
2001 and 30 September 2005 in Hamburg and between 1
August 2002 and 31 July 2005 in the R-N-K region. Further
inclusion criteria were age between 50 and 74 years and
being a resident of one of the study regions. Cases were iden-
tified through frequent monitoring of hospital admissions, sur-
gery schedules and pathology records. Clinical and
pathological characteristics of the patients were abstracted
from hospital and pathology records. Of the 5,970 eligible
patients who could be contacted, 3,919 (65.6%) participated
and 2,051 (34.4%) declined to participate or did not respond
to letters of invitation.
Two control individuals (controls) per case were randomly
selected from lists of residents provided by population regis-
tries and frequency matched by year of birth and study region
to the cases. Of the 17,093 controls who met the inclusion cri-
teria, 7,421 (43.4%) participated, 7,521 (44.0%) refused to
participate and 2,151 (12.6%) did not respond.
Using a standardized questionnaire all participants were inter-
viewed by trained personnel to obtain information on sociode-
mographic factors and potential breast cancer risk factors.
Women who reported their last natural menstrual bleeding at
least 12 months before the reference date (age at diagnosis
and recruitment for cases and controls, respectively), a bilat-
eral oophorectomy, or cessation of menses because of radia-
tion or chemotherapy were defined as postmenopausal.
Women older than 55 years with unclear menopausal status
because of hysterectomy or hormone use were also consid-
ered postmenopausal (because the 90th percentile for age at
menopause in women with natural menopause was 55 years).
Premenopausal women and women under age 55 years with
unclear menopausal status were excluded from the analysis. In
total, 3,464 invasive or in situ breast cancer cases and 6,657
controls were classified as postmenopausal, of whom 1,559
cases and 3,008 controls were from the R-N-K region.
Because of organizational aspects of sample handling, we
included only participants from the R-N-K study region.
Genotyping analysis
Postmenopausal participants from the R-N-K region with DNA
samples were included in this analysis, which included 1,408
(90.3%) cases and 2,612 (86.8%) controls.
Genomic DNA was extracted from blood samples using Flexi-
Gene DNA Kit (Qiagen, Hilden, Germany), in accordance with
the manufacturer's instruction. The TaqI SNP was genotyped
by PCR-restriction fragment length polymorphism. After PCR
reaction, 5 μl of the PCR product was digested with 1 unit ofAvailable online http://breast-cancer-research.com/content/10/2/R31
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TaqI restriction enzyme (New England Biolabs, Ipswich, MA,
USA). The resultant fragments (242 base pairs [TT genotype],
131 and 111 base pairs [CC], and 111, 131 and 242 base
pairs [TC]) were resolved on a 3.2% agarose gel. The FokI,
VDR-5132 and Cdx2 polymorphisms were genotyped using
Pyrosequencing™ technology (Biotage, Uppsala, Sweden)
[31]. PCR mixtures contained 5 ng DNA, 1× Ready Mix PCR
buffer (ABgene, Epsom, UK), 0.25 U Thermoprime DNA
polymerase (ABgene), deoxynucleoside triphosphates (each
at 167 μmol/l; PeqLab, Erlangen, Germany) and primers (3
pmol each), in a total reaction volume of 12 μl. Cycling condi-
tions were identical for all SNPs, namely 40 cycles (except for
Cdx2 [45 cycles]) of 94°C for 40 seconds, 57°C for 40 sec-
onds and 72°C for 40 seconds.
The following primers (5' → 3') were used: TaqI: forward
CTGCCGTTGAGTGTCTGTGT and reverse TCG-
GCTAGCTTCTGGATCAT; FokI: AGGGCGAATCATGTAT-
GAGG (PCR), GGTCAAAGTCTCCAGGGTCA
(biotinylated) and TTGCTGTTCTTACAGGG (sequencing);
VDR-5132: TGTCCTCATTTGGCCCCAGGA (PCR),
ACCGGGTGGATGCAGAAAGG  (bio) and GGGTGGTT-
GTCTA (seq); and Cdx2: CCCAAAAGGAAAGGAAGGAA
(PCR), AAAGCAAACCAAGGGGTCTT (bio) and CCTGAG-
TAAACTAGGTCACA (seq). For quality control, 10% of the
samples were selected at random for repeated genotyping
and concordance was 100%. Samples with ambiguous
results were repeated. The overall success rate for genotyping
was above 99% for all four polymorphisms analyzed.
Measurement of 25-hydroxyvitamin D
For quantification of 25(OH)D in serum, we used the OCTEIA
25-hydroxyvitamin D enzyme immunoassay (IDS, Immunodiag-
nostic Systems Limited, Boldon, UK). We analyzed a subset of
1,391 postmenopausal cases and 1,365 randomly selected
postmenopausal controls from the R-N-K region matched for
year of birth (continuous) and time of blood collection (January
to March, April to June, July to September, or October to
December) in a single batch between November 2006 and
January 2007. The coefficient of variation was 3.4% for intra-
assay determination and 7.6% for inter-assay determination.
We measured 235 random samples (8.5%) in duplicate. The
average absolute deviation from the mean between two dupli-
cates was 2.2%.
Data analysis
Polymorphisms were tested for deviation from Hardy-Wein-
berg equilibrium (HWE) by comparing the observed and
expected genotype frequencies using the χ2 test. To estimate
linkage disequilibrium for each pair of polymorphisms, we cal-
culated r2.
Women were categorized both by genotype (homozygote
minor allele, heterozygote, or homozygote major allele) and by
carrier status (homozygote major allele or carrier of the minor
allele) for the respective polymorphisms. We assessed the
association of SNPs in the VDR gene and postmenopausal
breast cancer risk by means of conditional logistic regression
with stratification by year of birth (continuous) and additional
stratification by time of blood collection (January to March,
April to June, July to September, or October to December) in
models assessing interaction with 25(OH)D. Homozygote
major allele carriers were used as the reference category. We
present odds ratios (ORs) and their corresponding 95% con-
fidence intervals (CIs) under the assumption of a general and
a dominant inheritance model. The following breast cancer risk
factor variables were included in the multivariate model: age at
menopause (< 47 years, 47 to 51 years, 52 to 55 years, ≥56
years, or unknown), body mass index (< 22.5 kg/m2, 22.5 to <
25 kg/m2, 25 to < 30 kg/m2, or ≥30 kg/m2), education level
(low, middle, or high), first-degree family history of breast can-
cer (yes, no, or unknown), history of benign breast disease
(yes or no), number of pregnancies (to week 28 or beyond; 0,
1, 2, ≥3), age at menarche (< 12 years, 12 to 14 years, of ≥15
years), breast feeding history (ever or never), total number of
mammograms (0, 1 to 4, 5 to 9, ≥10, or unknown), smoking
status (never, past, or current) and use of menopausal hor-
mone therapy (never, past, or current).
Haplotype analysis was conducted using the R haplo.stats
package [32]. Haplotypes and haplotype frequencies were
estimated using the R function haplo.em. The association of
common haplotypes with breast cancer risk was evaluated
with the R function haplo.glm. Haplo.glm applies a haplotype-
trait association test based on a general linear model frame-
work using maximum likelihood estimates for haplotype
effects, allowing for ambiguity of haplotype phase [33]. A log-
additive risk model was assumed, in which haplotype specific
regression coefficients represent the change in the log odds
of disease for every additional copy of the haplotype com-
pared with the homozygote reference haplotype. Because
haplo.glm uses an unconditional approach, we adjusted for
the same covariates as in the genotype analysis model but
additionally adjusted for the matching variable year of birth and
for time of blood collection in models assessing interaction
with 25(OH)D. The most common haplotype was set as the
reference haplotype.
Statistical genotype-environment interaction was evaluated
with the likelihood ratio test by including a cross-product term
of the dichotomous VDR genotype variable (carriers versus
noncarriers) and potential interaction variables of interest
(continuous variable for 25 [OH]D) in the multivariate model.
Statistical haplotype-environment interaction was evaluated
using Wald statistics for the respective interaction term in
haplo.glm, including interaction terms for all haplotypes simul-
taneously in the model.
Interaction of genotypes or haplotypes with oestrogen recep-
tor (ER) or progesterone receptor (PR) status of the tumourBreast Cancer Research    Vol 10 No 2    Abbas et al.
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was assessed by means of a case-only analysis. ER or PR sta-
tus was used as the dependent variable (outcome) and poten-
tial interaction variables (genotypes and haplotypes) as
independent variable in the logistic regression model. The
Wald statistic for the respective independent variable was
used to test for statistical interaction.
All tests were two-sided and considered to be statistically sig-
nificant at P ≤ 0.05. All calculations except the haplotype anal-
ysis were conducted using the statistical software SAS 9.1
(SAS Institute Inc., Cary, NC, USA).
Results
In comparison with controls, and consistent with established
risk factors for breast cancer, cases were significantly older at
menopause, were more likely to have a positive family history
of breast cancer, more frequently had a history of benign
breast disease, had lower parity, were younger at menarche,
were less likely to have breastfed, had a greater number of pre-
vious mammograms, and more frequently used hormone ther-
apy (Table 1).
Median 25(OH)D concentrations were 44.9 nmol/l and 51.5
nmol/l for cases and controls, respectively. We did not
observe significant differences in 25(OH)D concentrations by
genotype in any of the four analyzed polymorphisms (Table 2).
The genotype distribution in the control group was in HWE for
all analyzed polymorphisms (P = 0.30, P = 0.31, P = 0.39 and
P = 0.16 for FokI, TaqI, VDR-5132 and Cdx2, respectively).
The observed allele frequencies in the controls were compara-
ble to those reported in the dbSNP database for Caucasian
populations (minor allele frequencies of 0.39, 0.39, 0.41 and
0.19 for FokI, TaqI, VDR-5132 and Cdx2, respectively, in our
study population). There was no evidence of linkage disequi-
librium between any pair of the four analyzed polymorphism (r2
< 0.01).
We did not observe a significant association between geno-
types of any of the four analyzed polymorphisms and risk for
postmenopausal breast cancer (Table 3). In the subpopulation
for whom there were data on serum 25(OH)D (1,391 cases
and 1,365 controls), we further examined whether the associ-
ation between the VDR genotypes and breast cancer risk dif-
fered by serum 25(OH)D level. No departure from
multiplicative interaction was observed when considering
serum 25(OH)D level as a continuous variable (P for interac-
tion = 0.39, 0.43, 0.51 and 0.61 for FokI, TaqI, VDR-5132 and
Cdx2, respectively). Differential effects for the respective pol-
ymorphisms were also not found when serum 25(OH)D con-
centrations were dichotomized at 30 nmol/l, which was
defined as the cutt-off point for vitamin D deficiency. Analyses
stratified by season did not yield any further significant
25(OH)D-genotype interactions or differences in results
between the winter months (October to March) and the sum-
mer months (April to September). There was also no signifi-
cant gene-environment interaction with family history of breast
cancer, use of hormone therapy, or smoking status.
Because vitamin D possibly exerts its anticarcinogenic activi-
ties via the oestrogen pathway, we assessed possible differen-
tial effects by receptor status of the tumour. We observed a
statistically significant interaction for the TaqI polymorphism
and ER status in a case-only model (P for interaction = 0.04;
Table 4). Comparing t allele carriers with noncarriers, we
found a statistically significantly increased OR of 1.18 (95%
CI = 1.00 to 1.38) for ER-positive tumours, and an OR of 0.88
(95% CI = 0.69 to 1.13) for ER-negative tumours. No statisti-
cally significant interaction was observed between the TaqI
polymorphism and PR status of the tumour, or between the
FokI, Cdx2, or VDR-5132 polymorphism and PR or ER status
(Table 4). We also did not observe any differences in main or
interaction effects by stage of disease, when we performed
analysis stratified by local versus advanced tumours, accord-
ing to TNM-staging of the tumour (Union Internationale Contre
le Cancer classification).
We further estimated haplotypes by the expectation-maximiza-
tion algorithm and included 15 haplotypes with a frequency
above 1% in our analysis. The global test for an association of
any haplotype and postmenopausal breast cancer risk was not
significant (P global = 0.72). However, under the log-additive
model, the haplotype FtCA (FokI F, TaqI t, VDR-5132 C and
Cdx2 A) was significantly associated with breast cancer risk
compared with the most common haplotype FTCG (OR =
1.43, 95% CI = 1.00 to 2.05; Table 5). Under the dominant
model the OR was 1.53 (95% CI = 1.03 to 2.30) for those
with at least one copy of the FtCA haplotype as compared with
homozygote FTCG carriers. Power was inadequate using the
recessive model. No statistical interaction was observed
between any haplotypes and serum 25(OH)D concentration.
Analogous to the genotype analysis, we evaluated statistical
interaction of haplotypes with receptor status of the tumour in
a case-only analysis. We did not observe an interaction of any
haplotype with ER status. For the haplotype FtCA with the sig-
nificant main effect, the ORs were 1.34 (95% CI = 0.90 to
2.01) and 1.67 (95% CI = 0.94 to 2.99) for ER-positive and
ER-negative tumours, respectively (P for interaction = 0.64). A
statistically significant interaction was found for the haplotype
FtTA with PR status of the tumour (P for interaction = 0.03),
but haplotype frequency was very low (fFtTA = 0.016).
In a sensitivity analysis of haplotype associations, we addition-
ally adjusted for 25(OH)D concentration in the subpopulation
for whom there were data on 25(OH)D. ORs did not change
substantially, but the OR for the risk haplotype FtCA was no
longer significant because of lower numbers of cases and
controls.Available online http://breast-cancer-research.com/content/10/2/R31
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Table 1
Characteristics and risk factors for postmenopausal breast cancer in cases and matched controls in the study population
Characteristics Cases (na = 1,408) Controls (na+ = 2,612) Pb
n% n %
Age at diagnosis/recruitment (years) 0.87
50 to 54 104 7.4 191 7.3
55 to 59 301 21.4 528 20.2
60 to 64 447 31.7 859 32.9
65 to 69 380 27.0 720 27.6
≥70 176 12.5 314 12.0
BMI (kg/m2) 0.68
< 22.5 554 39.4 1,043 39.9
22.5 to < 25 473 33.6 829 31.8
25 to < 30 323 22.9 624 23.9
≥30 58 4.1 114 4.4
Educational level 0.07
Low 912 64.8 1,761 67.4
Middle 305 21.6 559 21.4
High 191 13.6 292 11.2
Age at menopause (years) < 0.01
< 47 146 10.4 396 15.2
47 to 51 407 28.9 748 28.6
52 to 55 248 17.6 402 15.4
≥56 63 4.5 115 4.4
Unknown 544 38.6 951 36.4
First degree family history of breast cancer < 0.01
No 1,113 79.1 2,164 82.8
Yes 234 16.6 329 12.6
Unknown 61 4.3 119 4.6
Benign breast disease < 0.01
No 860 61.3 1,833 70.5
Yes 544 38.7 766 29.5
Number of pregnancies (≥ 28th week) < 0.01
0 200 14.2 294 11.3
1 383 27.2 635 24.3
2 518 36.8 1,031 39.5
≥3 307 21.8 652 24.9
Age at menarche (years) 0.02
< 12 125 8.9 221 8.5
12 to 14 950 67.5 1,658 63.7
≥15 333 23.6 725 27.8Breast Cancer Research    Vol 10 No 2    Abbas et al.
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Discussion
In this population-based, case-control study, none of the poly-
morphisms in the VDR gene were associated with postmeno-
pausal breast cancer risk. However, there was effect
modification by ER status of the tumour, so that t allele car-
riage of the TaqI polymorphism was associated with signifi-
cantly higher breast cancer risk as compared with noncarriage
in ER-positive tumours only. Several studies reported no sig-
nificant association between the TaqI polymorphism and
breast cancer risk [10,12-17], and only one study comparing
Ever breastfeeding < 0.01
No 555 39.4 868 33.2
Yes 853 60.6 1,744 66.8
Number of mammograms in total < 0.01
0 195 13.8 334 12.8
1 to 4 598 42.5 1,370 52.5
5 to 9 343 24.4 599 22.9
≥10 254 18.0 288 11.0
Unknown number 18 1.3 21 0.8
Use of hormone therapy < 0.01
Never 528 37.9 1,113 43.1
Past 293 21.0 672 26.0
Current (≤ 6 months) 572 41.1 798 30.9
Hormonal receptor status of the tumorc
ER-positive 994 76.3
ER-negative 308 23.7
PR-positive 848 65.2
PR-negative 453 34.8
Time of blood collectiond 0.99
January to March 317 22.8 311 22.8
April to June 292 21.0 286 21.0
July to September 402 28.9 392 28.7
October to December 380 27.3 376 27.5
aNumbers do not always add up to total numbers because of missing values. bχ2 test for differences between cases and controls. cData on 
estrogen receptor (ER) and progesterone receptor (PR) status was available for 1,302 and 1,301 invasive tumour cases (in situ tumours 
excluded), respectively. dData on serum 25-hydroxyvitamin D status were available for 1,391 cases and 1,365 controls. BMI, body mass index.
Table 1 (Continued)
Characteristics and risk factors for postmenopausal breast cancer in cases and matched controls in the study population
Table 2
Serum 25(OH)D concentrations in the control group by polymorphisms in the vitamin D receptor gene
Polymorphism Genotype Pa
TaqI TT: 49.8 (32.6–67.5) Tt: 47.1 (32.5–66.1) tt: 48.1 (32.7–69.8) 0.52
FokI FF: 49.2 (33.0–66.9) Ff: 48.2 (32.4–67.4) ff: 47.9 (31.7–69.7) 0.85
VDR-5132 CC: 49.1 (32.9–66.9) CT: 48.6 (32.6–68.3) TT: 47.7 (31.6–66.9) 0.78
Cdx2 GG: 48.5 (32.5–67.4) GA: 48.7 (31.9–66.2) AA: 50.7 (35.0–68.6) 0.56
Values are expressed as median serum 25-hydroxyvitamin D (25 [OH]D; 25th to 75th percentile) in nmol/l. aWilcoxon rank-sum test for median 
differences by genotype.Available online http://breast-cancer-research.com/content/10/2/R31
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allele frequencies found a significantly higher risk for the T
allele [11]. However, these studies did not have sufficient
power to differentiate by receptor status of the tumour. Our
findings of an effect of TaqI polymorphism only for ER-positive
tumours suggest an oestrogen-mediated anticarcinogenic
effect of vitamin D. Indeed, there are laboratory data that sup-
port the hypothesis that the anticarcinogenic effects of vitamin
D could be mediated via the oestrogen pathway by downreg-
ulation of the ER and thus attenuating estrogenic biore-
sponses such as cell growth [34,35]. In addition, a putative
vitamin D response element, serving as a binding site for the
VDR-1,25(OH)2D-transcription factor complex, was found in
the ER promoter [36].
The functionality of the TaqI polymorphism is unclear. Although
TaqI is synonymous and in linkage disequilibrium with the two
nonfunctional intron-located polymorphisms BsmI and ApaI,
linkage disequilibrium extends into the 3' regulatory region,
which is known to be involved in regulation of VDR expression
[37]. Overall, functional studies – including studies on VDR
mRNA expression – are inconsistent but tend to indicate a
phenotype correlation with the frequently analyzed BAt haplo-
type (BsmI B ApaI A and TaqI t), including the TaqI t allele [37].
However, data for 41 individuals in whom VDR mRNA and pro-
tein level were measured indicated significantly lower levels in
both mRNA and protein in those with the tt genotype [38]. This
is consistent with our finding of higher breast cancer risk for
the TaqI t allele in ER-positive tumours, because less VDR
mRNA and protein may result in less 1,25(OH)2D-VDR com-
plexes and therefore in less anticarcinogenic activity.
To our knowledge, this is the first study to examine Cdx2 and
VDR-5132 polymorphisms and breast cancer risk. VDR-5132
leads to potential elimination of a GATA-1 transcription factor
binding site [25], whereas Cdx2 leads to decreased transcrip-
tional activity of the VDR promoter [26]. However, we found no
association of Cdx2 or VDR-5132 SNPs with breast cancer
risk in our study.
Table 3
Odds ratios for postmenopausal breast cancer by polymorphisms in the vitamin D receptor gene
Genotype Cases Controls Crude modela Adjusted modelb
n % n % OR (95% CI) OR (95% CI) Pc
TaqI 1,403 2,609 0.33
TT 497 35.4 980 37.6 1 1
Tt 667 47.6 1,218 46.7 1.08 (0.94–1.25) 1.08 (0.93–1.26)
tt 239 17.0 411 15.7 1.15 (0.95–1.39) 1.11 (0.91–1.36)
Tt/tt 1.10 (0.96–1.26) 1.09 (0.95–1.26)
FokI 1,390 2,596 0.24
FF 566 40.7 998 38.5 1 1
Ff 606 43.6 1,203 46.3 0.88 (0.77–1.02) 0.89 (0.77–1.03)
ff 218 15.7 395 15.2 0.98 (0.80–1.19) 0.97 (0.79–1.19)
Ff/ff 0.91 (0.80–1.04) 0.91 (0.79–1.05)
VDR-5132 1,400 2,607 0.92
CC 488 34.9 892 34.2 1 1
CT 683 48.8 1,284 49.3 0.99 (0.85–1.14) 1.00 (0.86–1.16)
TT 229 16.3 431 16.5 0.99 (0.81–1.20) 1.01 (0.83–1.24)
CT/TT 0.99 (0.86–1.13) 1.00 (0.87–1.16)
Cdx2 1,406 2,606 0.22
GG 888 63.1 1,701 65.3 1 1
GA 465 33.1 795 30.5 1.11 (0.97–1.28) 1.08 (0.94–1.25)
AA 53 3.8 110 4.2 0.94 (0.67–1.32) 0.94 (0.66–1.33)
GA/AA 1.09 (0.95–1.25) 1.07 (0.93–1.23)
aConditional logistic regression stratified by year of birth. bConditional logistic regression stratified by year of birth adjusted for age at menopause, 
first-degree family history of breast cancer, history of benign breast disease, number of pregnancies (≥28th week), age at menarche, breastfeeding 
history, total number of mammograms, use of hormone therapy, body mass index, education level and smoking status. cχ2 test for difference 
between cases and controls comparing the three genotypes for each polymorphism. CI, confidence interval; OR, odds ratio.Breast Cancer Research    Vol 10 No 2    Abbas et al.
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Our results for the FokI polymorphism do not support the find-
ings of a large case-control study nested in the NHS reporting
a significantly increased risk with the ff versus the FF genotype
[20]. Although this polymorphism is known to be functional
[18,39], numerous other studies, including the present one,
were unable to confirm the finding from the NHS [11,14,21-
23].
In a haplotype analysis, we found the haplotype FtCA (FokI F,
TaqI t, VDR-5132 C, Cdx2 A) to be associated with a signifi-
cantly greater breast cancer risk as compared with the most
frequent haplotype (FTCG). The reason for this finding is
unclear. The FtCA haplotype (versus the FTCG reference hap-
lotype) contains the transcriptionally more active Cdx2 A allele
[26], which is expected to be associated with a decreased risk
for breast cancer. On the other hand, in accordance with the
observed increased risk associated with TaqI t allele carriage
in ER-positive tumours, the t allele is also present in the FtCA
risk haplotype. Nevertheless, because of the multiple compar-
isons in our analysis, we cannot exclude the possibility that the
observed significant associations may be chance findings.
We recently reported an inverse association between serum
25(OH)D concentration and postmenopausal breast cancer
risk [30] and therefore were interested in assessing possible
interaction between 25(OH)D status and genotype. Gene-
environment interactions may explain inconsistencies in asso-
ciations between polymorphisms and breast cancer risk in dif-
ferent studies. However, we did not find evidence for
interactions of VDR  polymorphisms with 25(OH)D (the
observed inverse association of 25 [OH]D and breast cancer
risk was not modified by genotype). Our results corroborate
the findings in the NHS of an absence of interaction between
the FokI SNP and 25(OH)D [20]. Functional variants of the
VDR might affect 25(OH)D concentration, because the VDR
is possibly involved in negative feedback regulation of
1,25(OH)2D synthesis mediated by the 1α-hydroxylase, which
is the enzyme that converts 25(OH)D to active 1,25(OH)2D
[40]. However, 25(OH)D levels did not vary by VDR genotype
in our population, which is consistent with results on the rela-
tion between FokI and TaqI polymorphisms and vitamin D sta-
tus in previous smaller studies [38,41].
Strengths of our study are the large sample size, the adjust-
ment for all potential breast cancer risk factors, the evaluation
of interactions with serum 25(OH)D, and the restriction to
postmenopausal women, because various studies so far have
not differentiated between premenopausal and postmenopau-
sal women. Genotyping errors can almost completely be
excluded, because 10% of the samples were genotyped in
duplicate and concordance was 100%. In addition, all ana-
lyzed polymorphisms were in HWE and allele frequencies
were comparable to those reported in the dbSNP database for
Caucasian populations.
Table 4
Odds ratios for postmenopausal breast cancer by genotypes in the vitamin D receptor gene according to ER and PR status of the 
tumour
Genotype ER-positive tumours ER-negative tumours PR-positive tumours PR-negative tumours
n 
(controls)
n 
(cases)
OR (95% CI) n 
(cases)
OR (95% CI) n 
(cases)
OR (95% CI) n 
(cases)
OR (95% CI)
TaqI
TT 980 337 1 121 1 297 1 159 1
Tt/tt 1,629 653 1.18 (1.00–1.38) 186 0.88 (0.69–1.13) 547 1.10 (0.93–1.30) 293 1.11 (0.89–1.37)
FokI
FF 998 394 1 127 1 331 1 190 1
Ff/ff 1,598 586 0.95 (0.81–1.10) 177 0.86 (0.67–1.10) 505 0.96 (0.82–1.14) 257 0.84 (0.68–1.03)
VDR-5132
CC 892 347 1 113 1 298 1 162 1
CT/TT 1,715 640 0.99 (0.84–1.16) 194 0.92 (0.71–1.18) 543 0.97 (0.82–1.15) 290 0.97 (0.78–1.20)
Cdx2
GG 1,701 641 1 190 1 546 1 283 1
GA/AA 905 351 1.01 (0.86–1.17) 118 1.14 (0.88–1.46) 301 1.01 (0.86–1.20) 169 1.11 (0.90–1.38)
We conducted a conditional logistic regression stratified by year of birth adjusted for age at menopause, first-degree family history of breast 
cancer, history of benign breast disease, number of pregnancies (≥28th week), age at menarche, breastfeeding history, total number of 
mammograms, use of hormone therapy, body mass index, education level and smoking status. Data on oestrogen receptor (ER) and progesterone 
receptor (PR) status was available for 1,302 and 1,301 cases, respectively.Available online http://breast-cancer-research.com/content/10/2/R31
Page 9 of 11
(page number not for citation purposes)
We selected mainly functional variants in order to assess their
effects on breast cancer risk. However, observed associations
may have arisen from other unknown functional variants in link-
age with the analyzed polymorphisms in our study. In contrast,
the haplotype analysis was exploratory because functionality
of the analyzed haplotypes is unknown. Therefore, further stud-
ies with respect to functionality of haplotypes are necessary.
Limitations due to the retrospective case-control design are of
less importance when assessing genetic variations, and thus
selection bias is unlikely to have biased our results. However,
when interpretating the null interactions with serum 25(OH)D,
the low response rate in the population controls and measure-
ment of 25(OH)D after diagnosis in the cases may be of con-
cern. Information on 25(OH)D status, diet, or vitamin D related
variables such as outdoor activity in nonparticipants was not
available. A cancer diagnosis may change dietary or behav-
ioural habits, which may influence 25(OH)D concentrations.
Modification of dietary habits after a cancer diagnosis appears
to be limited [42], but cases might have had less opportunity
for outdoor activities (sun exposure) after diagnosis, leading to
potential differences in 25(OH)D status between cases and
controls. The median difference between time of diagnosis
and time of blood collection in the cases was, however, fairly
low (median [25th to 75th percentile] = 80 [14 to 260] days).
The null results for the interaction between genotypes/haplo-
types and 25(OH)D might also have been biased by potential
influence of chemotherapy on 25(OH)D concentration. How-
ever, a notable change in 25(OH)D concentration after chem-
otherapeutic treatment was not observed in two studies
[43,44].
Our findings are not representative for non-Caucasian popula-
tions because women in our population are primarily Cauca-
sian and allele frequencies vary widely among populations of
different ethnic origin.
Conclusion
None of the analyzed polymorphisms was associated with risk
for breast cancer overall. However, the t allele of the TaqI pol-
ymorphism was associated with a significantly increased
breast cancer risk in ER-positive tumours only. In a haplotype
analysis the haplotype FtCA (FokI F, TaqI t, VDR-5132 C,
Cdx2 A) was associated with a significantly higher breast can-
cer risk as compared with the most frequent haplotype
(FTCG). No significant interaction between VDR SNPs or hap-
lotypes and serum 25(OH)D was found. Our results support
potential effects of VDR polymorphisms on postmenopausal
breast cancer risk. Further epidemiological studies assessing
the association of vitamin D and breast cancer risk should take
the receptor status of the tumour and other gene variants of
oestrogen metabolism into account. In addition, more studies
Table 5
Odds ratios for postmenopausal breast cancer by haplotypes in the vitamin D receptorgene under the log-additive model
Haplotypea Haplotype frequencies (%) OR (95% CI)
Cases (n = 1,408) Controls (n = 2,612) Crude modelb Adjusted modelc
FTCG 0.178 0.183 1 1
FTCA 0.036 0.049 0.76 (0.51–1.15) 0.81 (0.53–1.23)
FTTG 0.124 0.116 1.12 (0.87–1.43) 1.09 (0.84–1.40)
FTTA 0.025 0.025 1.10 (0.69–1.77) 1.16 (0.71–1.88)
FtCG 0.117 0.113 1.07 (0.83–1.38) 1.06 (0.82–1.39)
FtCA 0.052 0.035 1.50 (1.07–2.12) 1.43 (1.00–2.05)
FtTG 0.076 0.079 0.98 (0.76–1.27) 1.04 (0.80–1.36)
FtTA 0.016 0.015 1.05 (0.59–1.87) 0.98 (0.54–1.79)
fTCG 0.109 0.117 0.97 (0.75–1.24) 0.97 (0.75–1.26)
fTCA 0.028 0.023 1.19 (0.72–1.96) 1.17 (0.70–1.95)
fTTG 0.080 0.083 0.98 (0.75–1.26) 1.04 (0.80–1.35)
fTTA 0.011 0.011 1.07 (0.48–2.37) 0.93 (0.41–2.09)
ftCG 0.048 0.041 1.19 (0.84–1.69) 1.19 (0.82–1.72)
ftCA 0.024 0.027 0.94 (0.57–1.55) 0.95 (0.56–1.64)
ftTG 0.065 0.072 0.94 (0.71–1.25) 0.94 (0.70–1.27)
aFokI, TaqI, VDR-5132, Cdx2 (with > 1% frequency in the study population). bUnconditional haplotype analysis adjusted for matching factor year 
of birth. cUnconditional haplotype analysis adjusted for year of birth, age at menopause, first-degree family history of breast cancer, history of 
benign breast disease, number of pregnancies (≥28th week), age at menarche, breastfeeding history, total number of mammograms, use of 
hormone therapy, body mass index, education level and smoking status. CI, confidence interval; OR, odds ratio.Breast Cancer Research    Vol 10 No 2    Abbas et al.
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on certain polymorphisms and haplotypes in the VDR, espe-
cially functional studies with respect to impact on VDR activity
and concentration, are needed.
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